Peter Lau
@DrPeterLauMedical Oncologist | Clinician/Scientist | Researcher | @LinearClinical, BCRC-WA & Harry Perkins | Ex @PeterMac | Armchair Basketball Critic | Tweets my own op
Similar User
@rare_arc
@VCCCAlliance
@Prof_G_McArthur
@stephenqwong
@thelimbiconc
@ProfClareScott
@JuliaLaiKwon
@ProfGLongMIA
@ausyoungoncs
@AOParsonson
@shalinivinod13
@LindaMileshkin
@DrCraigGedye
@anmwongNZ
@DrNickClemons
Terrific presentations tackling melanoma resistance to IO at #AMC2024. There’s so much to do. #melanoma
Great session on New Melanoma Treatment approaches at #AMC2024 @ElinSGrayPhD, @HelenRizos, @DrJonasANilsson, A/Prof Jason Lee and A/Prof Jason Waithman
Are high dose steroids for immunotherapy related toxicity harmful in the long run? This paper suggests they are for #Cancer. But was the dose of the steroid proportionate to the severity of the IO toxicity? 🤷🏻 @anmwongNZ, @SpainLavinia #Melanoma ascopubs.org/doi/10.1200/JC…
Please support Dr Dave Lau @PeterMacCC and Prof Ramsay who are walking this weekend for this great cause to raise funds for cancer research. @GICancer
Tomorrow, our incredible team of Gutsy fundraisers will begin their 4-day trek through the Grampians. Led by AGITG Board Member, Professor Rob Ramsay, they have raised over $21,000 for GI cancer research! Will you support them on their trek? Visit: …iansgutsychallenge.gofundraise.com.au
So pleased to be working with @DrJonasANilsson and Dr Zlatibor Velickovic in bringing cell therapy to Perth. There is much more work to be done! perthnow.com.au/local-news/per…
Big news today with the FDA approval of lifileucel: a cell therapy for immunotherapy resistant melanoma. A genuine game changer for patients in the US but will be interesting to see how other countries adopt it. fda.gov/news-events/pr…
Datopotomab-durvalumab looks very promising for triple negative breast cancer. Nearly an 80% response rate. Early days but encouraging. Looking forward to seeing more data for this ADC-IO combination. #bcsm
Terrific news for Australian uveal melanoma patients with the Pharmaceutical Benefits Advisory Committee (PBAC) positive recommendation for tebentafusp to be listed on the PBS. pbs.gov.au/info/industry/…
So long until next time Adelaide. Learnt a lot about lobular breast cancers, HER2 IHC 0-3 and ADCs at the Australian Breast Disease ASM 2023. Had a great time with old friends and new.
Congratulations to Dr Sam Bowyer and @LinearClinical for their work in this promising new G12C Inhibitor Divarasib. Response rates of 53% and mPFS of 13.1 months in G12C NSCLC looks promising amongst other tumour types. Well done! nejm.org/doi/full/10.10…
This paper on the negative impact of THC and immunotherapy responses will no doubt be cited in many doctor-patient consultations.
#foodforthought🎯Immunomodulatory, anti-inflammatory, immunosuppressive effects of cannabinoids have been reported for decades across various illnesses.👇A few studies that dive into purported mechanisms: 🔗nature.com/articles/s4139 a 2022 preclinical study on both cannabis-derived…
Had the ❤️ feels when a colleague sent me this photo from a meeting back in Melbourne yesterday. So nice to know one hasn’t been forgotten from a great team in a terrific organisation!
Bravo @drtclay and @oncologyknitwit for organising a terrific #MOGA23 in Perth. Great way to end the meeting with talks and tunes from @matteolambe and @TommyJohn00!
Never thought to refer to Star Wars or Taylor Swift in a scientific paper title! 🤗
#foodforthought🎯Immunomodulatory, anti-inflammatory, immunosuppressive effects of cannabinoids have been reported for decades across various illnesses.👇A few studies that dive into purported mechanisms: 🔗nature.com/articles/s4139 a 2022 preclinical study on both cannabis-derived…
I know Perth is on the opposite side of the Earth to Chicago, but to my surprise this arrived in the mail yesterday. 😝 #ASCO #betterlatethennever
Absolute pleasure to present CHARLI: A Phase 1b/2 study of nivolumab-denosumab or ipilimumab-nivolumab-denosumab in metastatic melanoma. Please stop by poster board 288 in the melanoma session at #ASCO2023 Thank you @PeterMacCC @MASC_Trials #melanoma meetings.asco.org/2023-asco-annu…
Absolute pleasure to present CHARLI: A Phase 1b/2 study of nivolumab-denosumab or ipilimumab-nivolumab-denosumab in metastatic melanoma. Please stop by poster board 288 in the melanoma session at #ASCO2023 Thank you @PeterMacCC @MASC_Trials #melanoma meetings.asco.org/2023-asco-annu…
United States Trends
- 1. $CATEX N/A
- 2. $CUTO 7.487 posts
- 3. #collegegameday 2.182 posts
- 4. $XDC 1.383 posts
- 5. DeFi 105 B posts
- 6. #Caturday 7.757 posts
- 7. Henry Silver N/A
- 8. Jayce 81,5 B posts
- 9. #saturdaymorning 3.110 posts
- 10. Good Saturday 36,5 B posts
- 11. #Arcane 301 B posts
- 12. #MSIxSTALKER2 5.998 posts
- 13. Renji 3.731 posts
- 14. Senior Day 2.904 posts
- 15. Pence 85,3 B posts
- 16. Fritz 8.659 posts
- 17. Cavuto N/A
- 18. Zverev 6.991 posts
- 19. Fishers N/A
- 20. Tyquan Thornton N/A
Who to follow
-
Australian Rare Cancer (ARC) Portal
@rare_arc -
VCCC Alliance
@VCCCAlliance -
Chief Executive Officer VCCC Alliance
@Prof_G_McArthur -
Stephen Wong
@stephenqwong -
the limbic
@thelimbiconc -
Clare Scott
@ProfClareScott -
Dr Julia Lai-Kwon
@JuliaLaiKwon -
Professor Georgina Long AO
@ProfGLongMIA -
ausyoungoncs
@ausyoungoncs -
Dr Andrew Parsonson
@AOParsonson -
Shalini Vinod
@shalinivinod13 -
Linda Mileshkin
@LindaMileshkin -
Craig Gedye
@DrCraigGedye -
Annie Wong 黃毅敏
@anmwongNZ -
Nick
@DrNickClemons
Something went wrong.
Something went wrong.